首页> 美国卫生研究院文献>Canadian Urological Association Journal >Images – pT3a clear-cell renal cell carcinoma in a renal allograft managed effectively with open partial nephrectomy
【2h】

Images – pT3a clear-cell renal cell carcinoma in a renal allograft managed effectively with open partial nephrectomy

机译:图片–肾同种异体移植物中的pT3a透明细胞肾细胞癌通过开放性部分肾切除术得到有效管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary renal cell carcinoma (RCC) post-kidney transplantation can occur in either the native kidney(s) or renal allograft, although their occurrence is significantly rarer in the latter. Immunosuppressive therapy is known to increase the incidence of various malignancies in patients on these regimens due to their effects on the immune system and their role in anti-cancer immune surveillance. Neoplasms can develop as the result of accidental transplantation from donor with undetected primary cancer, recurrence or undiagnosed metastases, or de novo. As well, these tumors tend to be more aggressive, confer a poor prognosis, and are associated with a higher rate of recurrence than the same tumors in the general population.
机译:肾脏原发性肾细胞癌(RCC)移植可以在天然肾脏或同种异体肾中发生,尽管在后者中发生的情况明显较少。免疫抑制疗法因其对免疫系统的影响及其在抗癌免疫监视中的作用,已知会增加这些方案下患者各种恶性肿瘤的发生率。肿瘤可能是由于来自供体的意外移植,未发现的原发癌,复发或未经诊断的转移或新生而导致的。同样,与普通人群中的相同肿瘤相比,这些肿瘤往往更具侵袭性,预后差,并且具有较高的复发率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号